Author:
Cardoso Fatima,Senkus Elżbieta
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172 (2014).
2. Piccart-Gebhart, M. J. et al. First results from the phase III ALTTO trial (BIG 2–06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) [abstract]. J. Clin. Oncol. 32 (Suppl.), LBA4 (2014).
3. Piccart, M. et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann. Oncol. 25, 2357–2362 (2014).
4. Swain, S. et al. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (d) in patients (pts) with HER2-positive metastatic breast cancer (MBC) [abstract]. Ann. Oncol. 25 (Suppl. 4), 3500_PR (2014).
5. Baselga, J. et al. A phase III randomized, double-blind, trial comparing sorafinib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE) [abstract]. Ann. Oncol. 25 (Suppl. 4), LBA8 (2014).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献